公开(公告)号：EP1654005A4

公开(公告)日：2011-06-15

申请号：EP04779135

申请日：2004-07-23

申请人： BRACCO IMAGING SPA

发明人： CHEN JIANQING ,  LINDER KAREN E ,  MARINELLI EDMUND R ,  METCALFE EDMUND ,  NUNN ADRIAN ,  SWENSON ROLF E ,  TWEEDLE MICHAEL

IPC分类号： A61K51/00 ,  A61K20060101 ,  A61K51/08 ,  A61K51/12

CPC分类号： A61K51/12 ,  A61K51/088

公开(公告)号：EP1585549A4

公开(公告)日：2009-07-29

申请号：EP03800223

申请日：2003-12-24

申请人： BRACCO IMAGING SPA

发明人： CAPPELLETTI ENRICO ,  LATTUADA LUCIANO ,  LINDER KAREN E ,  MARINELLI ED ,  NANJAPPAN PALANIAPPA ,  RAJU NATARAJAN ,  SWENSON ROLF E ,  TWEEDLE MICHAEL

IPC分类号： A61K49/00 ,  A61K51/08 ,  C07K7/08

CPC分类号： A61K51/088 ,  C07K7/086

公开(公告)号：EP1898962A4

公开(公告)日：2013-01-09

申请号：EP06785507

申请日：2006-06-23

申请人： BRACCO IMAGING SPA

发明人： CAPPELLETTI ENRICO ,  LATTUADA LUCIANO ,  LINDER KAREN E ,  MARINELLI EDMUND R ,  NANJAPPAN PALANIAPPA ,  RAJU NATARAJAN ,  RAMALINGAM KONDAREDDIAR ,  SWENSON ROLF E ,  TWEEDLE MICHAEL F

IPC分类号： A61K51/00 ,  A61K36/14 ,  A61K51/08

CPC分类号： A61K51/088 ,  A61K49/0002 ,  C07C269/04 ,  C07D257/00 ,  C07J41/0005 ,  C07J41/0011 ,  C07J43/003 ,  C07K14/57572 ,  C07C271/22

公开(公告)号：EP1404376A4

公开(公告)日：2007-07-04

申请号：EP01987641

申请日：2001-10-19

申请人： BRACCO IMAGING SPA

发明人： CAGNOLINI ALDO ,  LINDER KAREN E ,  MARINELLI EDMUND R

IPC分类号： A61K51/04 ,  A61K51/12 ,  A61K51/00

CPC分类号： A61K51/1282 ,  A61K51/0478

公开(公告)号：EP2291075A4

公开(公告)日：2012-08-22

申请号：EP09751329

申请日：2009-05-19

申请人： BRACCO IMAGING SPA

发明人： LATTUADA LUCIANO ,  CAPPELLETTI ENRICO ,  LINDER KAREN E ,  NUNN ADRIAN D ,  LANTRY LAURA

IPC分类号： A01N37/18 ,  A61K38/00 ,  C07K7/08

CPC分类号： A61K51/088 ,  A61K49/0056 ,  G01N33/57492 ,  G01N2333/5758

摘要： Methods and compositions for diagnosing, staging disease, monitoring therapeutic effect of drugs and imaging a patient are provided, including radiopharmaceutical formulations. Compositions comprising Ga-AMBA complexed with a radioactive isotope are provided; as are methods of imaging Gastrin Releasing Peptide receptor (GRP-R) bearing tissue and methods of diagnosing or staging disease in patients suspected of having disease associated with aberrant GRP-R function. Further, methods of monitoring therapeutic effect of a drug targeted to a receptor that crosstalks with GRP-R are provided; as are methods of pre-dosing/co-dosing non-target tissues containing GRP-R. Particularly, methods of monitoring activity of receptors and receptor pathways in vivo/in vitro by using a ligand that binds to the GRP-R are provided; as are methods of measuring the activity of a receptor or group of receptors and their associated pathways that exhibit crosstalk with the GRP-R by using such a ligand which is also detectable by external means.